CPA
LRMR icon

Capital Performance Advisors’s Larimar Therapeutics LRMR Stock Holding History

Capital Performance Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18
Closed -$118 – 1575
2024
Q3 		$118 Buy
+18
New +$145 ﹤0.01% 2664

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Capital Performance Advisors's LRMR Position: Q4 2024 in Review

Capital Performance Advisors sold out of Larimar Therapeutics (LRMR) in Q4 2024, closing a stake of 18 shares — an estimated $118 sold.

Capital Performance Advisors first reported a position in LRMR in Q3 2024 and held it in 1 quarter. The position peaked at $118 in Q3 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q4 2024.

  • Capital Performance Advisors reported no remaining Larimar Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 18 Larimar Therapeutics shares in Q4 2024, an estimated $118.
  • Capital Performance Advisors first reported a position in Larimar Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Larimar Therapeutics position peaked at $118 in Q3 2024.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.